PlainPharmaWatch

CMS Open Payments · Tool

Zealand Pharma A/S vs Aesculap, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Zealand Pharma A/S has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 6,299, versus 634 for the other company. Its single largest recorded recipient represents 79.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Zealand Pharma A/S
HHI 6,299 · top recipient 79.1%
Ranked #254 of 1,838 companies by HHI
Aesculap, Inc.
HHI 634 · top recipient 20.6%
Ranked #1,213 of 1,838 companies by HHI

Payment Overview

Company A

Zealand Pharma A/S

Total Payments
$919.9K
% of Industry
0.0%
Transactions
178
Avg per Transaction
$5.2K
Recipients
108
Avg per Recipient
$8.5K
Payment Types
4
Top Payment Type
Consulting Fee
Company B

Aesculap, Inc.

Total Payments
$921.5K
% of Industry
0.0%
Transactions
705
Avg per Transaction
$1.3K
Recipients
705
Avg per Recipient
$1.3K
Payment Types
5
Top Payment Type
Debt Forgiveness

Highlighted values indicate the higher figure for each metric.

Total payments compared

Zealand Pharma A/S vs Aesculap, Inc. - total reported payments in CMS Open Payments PY2024

Aesculap, Inc.$921.5KZealand Pharma A/S$919.9K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Zealand Pharma A/S

Consulting Fee $308.1K

81.9%

Travel and Lodging $56.6K

15.0%

Food and Beverage $6.2K

1.6%

Compensation for Services Other Than Consulting $5.4K

1.4%

Aesculap, Inc.

Debt Forgiveness $706.0K

76.6%

Consulting Fee $158.3K

17.2%

Food and Beverage $22.7K

2.5%

Travel and Lodging $21.5K

2.3%

Space Rental or Facility Fees $13.0K

1.4%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Zealand Pharma A/S

  1. 1

    STEVEN SMITH

    $297,580.51 · 48 txns

  2. 2

    ANIA JASTREBOFF

    $13,909.68 · 5 txns

  3. 3

    PAUL THORNTON

    $13,400.00 · 1 txns

  4. 4

    ILDIKO LINGVAY

    $9,777.30 · 6 txns

  5. 5

    WILLIAM GARVEY

    $6,371.91 · 6 txns

Aesculap, Inc.

  1. 1

    HOBOKEN UNIVERSITY MEDICAL CENTER

    $189,786.61 · 1 txns

  2. 2

    MEDICAL CENTER HEALTH SYSTEM

    $62,456.81 · 2 txns

  3. 3

    STEWARD HOLY FAMILY HOSPITAL

    $58,079.37 · 1 txns

  4. 4

    ST JOSEPH MEDICAL CENTER

    $41,739.72 · 1 txns

  5. 5

    KFH - DOWNEY

    $34,500.00 · 1 txns

Summary Comparison

Metric Zealand Pharma A/S Aesculap, Inc.
Total Payments $919.9K $921.5K
% of Industry Total 0.0% 0.0%
Transaction Count 178 705
Avg per Transaction $5.2K $1.3K
Recipient Count 108 705
Avg per Recipient $8.5K $1.3K
Payment Type Count 4 5
Top Payment Type Consulting Fee Debt Forgiveness

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.